Barclays PLC Spero Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.74 - $7.44 $2,757 - $27,721	-3,726 Reduced 94.81%	204 $0
Q1 2022 May 16, 2022	SELL	$7.87 - $15.15 $200,220 - $385,431	-25,441 Reduced 86.62%	3,930 $35,000
Q4 2021 Feb 14, 2022	BUY	$13.09 - $18.77 $254,024 - $364,250	19,406 Added 194.74%	29,371 $470,000
Q3 2021 Nov 09, 2021	BUY	$13.03 - $19.51 $57,345 - $85,863	4,401 Added 79.1%	9,965 $183,000
Q2 2021 Aug 13, 2021	SELL	$12.22 - $15.79 $196,448 - $253,840	-16,076 Reduced 74.29%	5,564 $77,000
Q1 2021 May 13, 2021	BUY	$13.23 - $21.48 $197,656 - $320,911	14,940 Added 222.99%	21,640 $319,000
Q4 2020 Feb 11, 2021	SELL	$11.65 - $22.07 $21,645 - $41,006	-1,858 Reduced 21.71%	6,700 $130,000
Q3 2020 Nov 12, 2020	SELL	$8.96 - $14.12 $10,312 - $16,252	-1,151 Reduced 11.85%	8,558 $96,000
Q2 2020 Aug 12, 2020	BUY	$7.27 - $14.18 $39,178 - $76,416	5,389 Added 124.75%	9,709 $130,000
Q1 2020 May 13, 2020	SELL	$5.27 - $10.41 $37,106 - $73,296	-7,041 Reduced 61.98%	4,320 $34,000
Q4 2019 Feb 10, 2020	BUY	$9.46 - $12.16 $55,369 - $71,172	5,853 Added 106.26%	11,361 $109,000
Q3 2019 Nov 14, 2019	SELL	$9.01 - $12.55 $11,541 - $16,076	-1,281 Reduced 18.87%	5,508 $58,000
Q2 2019 Aug 14, 2019	BUY	$10.25 - $14.36 $43,275 - $60,627	4,222 Added 164.47%	6,789 $78,000
Q1 2019 May 15, 2019	BUY	$6.26 - $13.31 $13,340 - $28,363	2,131 Added 488.76%	2,567 $33,000
Q4 2018 Feb 14, 2019	SELL	$5.69 - $11.28 $17,758 - $35,204	-3,121 Reduced 87.74%	436 $2,000
Q3 2018 Nov 14, 2018	BUY	$9.69 - $17.79 $29,738 - $54,597	3,069 Added 628.89%	3,557 $37,000
Q2 2018 Aug 14, 2018	SELL	$10.41 - $17.85 $8,359 - $14,333	-803 Reduced 62.2%	488 $7,000
Q1 2018 May 15, 2018	BUY	$9.96 - $14.61 $3,336 - $4,894	335 Added 35.04%	1,291 $19,000
Q4 2017 Feb 14, 2018	BUY	$10.43 - $14.75 $9,971 - $14,101	956	956 $11,000

Others Institutions Holding SPRO

# of Institutions

Shares Held

13.9M

Call Options Held

200

Put Options Held

200

Anson Funds Management LP Dallas, TX

3.75M
Shares

$3.56 Million
0.6% of portfolio
Vanguard Group Inc Valley Forge, PA

1.76M
Shares

$1.68 Million
0.0% of portfolio
Atlas Venture Associates Ix, LLC Boston, MA

1.35M
Shares

$1.29 Million
14.54% of portfolio
Acadian Asset Management LLC Boston, MA

1.07M
Shares

$1.02 Million
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

975K
Shares

$925,920
0.0% of portfolio

View Full List

About Spero Therapeutics, Inc.

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $33.3M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

More about SPRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account